Zwarthoff E - Search Results

1

Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.

Christensen E, Birkenkamp-Demtröder K, Nordentoft I, Høyer S, van der Keur K, van Kessel K, Zwarthoff E, Agerbæk M, Ørntoft TF, Jensen JB, Dyrskjøt L. Christensen E, et al. Among authors: zwarthoff e. Eur Urol. 2017 Jun;71(6):961-969. doi: 10.1016/j.eururo.2016.12.016. Epub 2017 Jan 6. Eur Urol. 2017. PMID: 28069289

2

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.

van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. van Rhijn BW, et al. Among authors: zwarthoff ec. Cancer Res. 2001 Feb 15;61(4):1265-8. Cancer Res. 2001. PMID: 11245416

3

Frequent FGFR3 mutations in urothelial papilloma.

van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH. van Rhijn BW, et al. J Pathol. 2002 Oct;198(2):245-51. doi: 10.1002/path.1202. J Pathol. 2002. PMID: 12237885

4

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.

van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff EC, Radvanyi F. van Rhijn BW, et al. Eur J Hum Genet. 2002 Dec;10(12):819-24. doi: 10.1038/sj.ejhg.5200883. Eur J Hum Genet. 2002. PMID: 12461689

5

Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.

van Rhijn BW, Lurkin I, Chopin DK, Kirkels WJ, Thiery JP, van der Kwast TH, Radvanyi F, Zwarthoff EC. van Rhijn BW, et al. Clin Cancer Res. 2003 Jan;9(1):257-63. Clin Cancer Res. 2003. PMID: 12538478

6

Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy.

van Rhijn BW, Smit M, van Geenen D, Wijnmaalen A, Kirkels WJ, van der Kwast TH, Kuenen-Boumeester V, Zwarthoff EC. van Rhijn BW, et al. Eur Urol. 2003 Apr;43(4):369-73. doi: 10.1016/s0302-2838(03)00059-9. Eur Urol. 2003. PMID: 12667717

7

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.

van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER, Jöbsis AC, Zwarthoff EC. van Rhijn BW, et al. Cancer Res. 2004 Mar 15;64(6):1911-4. doi: 10.1158/0008-5472.can-03-2421. Cancer Res. 2004. PMID: 15026322 Free article.

8

A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation.

van der Aa MN, van Leenders GJ, Steyerberg EW, van Rhijn BW, Jöbsis AC, Zwarthoff EC, van der Kwast TH. van der Aa MN, et al. Hum Pathol. 2005 Sep;36(9):981-6. doi: 10.1016/j.humpath.2005.06.017. Hum Pathol. 2005. PMID: 16153461

9

A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.

van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC. van Oers JM, et al. Clin Cancer Res. 2005 Nov 1;11(21):7743-8. doi: 10.1158/1078-0432.CCR-05-1045. Clin Cancer Res. 2005. PMID: 16278395

10

Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.

van Oers JM, Adam C, Denzinger S, Stoehr R, Bertz S, Zaak D, Stief C, Hofstaedter F, Zwarthoff EC, van der Kwast TH, Knuechel R, Hartmann A. van Oers JM, et al. Int J Cancer. 2006 Sep 1;119(5):1212-5. doi: 10.1002/ijc.21958. Int J Cancer. 2006. PMID: 16570285

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238 results

Search Page

Filters